{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:26:46Z","timestamp":1787498806387,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.05.087","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T02:42:28Z","timestamp":1654483348000},"page":"4440-4452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity"],"prefix":"10.1016","volume":"40","author":[{"given":"Balamurugan","family":"Shanmugaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narach","family":"Khorattanakulchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalisa","family":"Panapitakkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawiwan","family":"Im-erbsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manutsanun","family":"Inthawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanate","family":"Sunyakumthorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taweewun","family":"Hunsawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonticha","family":"Klungthong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taratorn","family":"Kemthong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutchanat","family":"Suttisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchinda","family":"Malaivijitnond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Passaraporn","family":"Srimangkornkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aekkarin","family":"Klinkhamhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwimon","family":"Manopwisedjaroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunee","family":"Thitithanyanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthira","family":"Taychakhoonavudh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waranyoo","family":"Phoolcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2022.05.087_b0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.087_b0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","article-title":"COVID-19, SARS and MERS: are they closely related?","volume":"26","author":"Petrosillo","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2022.05.087_b0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat Microbiol"},{"issue":"10223","key":"10.1016\/j.vaccine.2022.05.087_b0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"7798","key":"10.1016\/j.vaccine.2022.05.087_b0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.087_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"suppl 1","key":"10.1016\/j.vaccine.2022.05.087_b0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.22207\/JPAM.14.SPL1.30","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an emerging zoonotic respiratory pathogen in humans","volume":"14","author":"Malla","year":"2020","journal-title":"J Pure Appl Microbiol"},{"key":"10.1016\/j.vaccine.2022.05.087_b0040","unstructured":"World Health Organization W. WHO Coronavirus Disease (COVID-19) Dashboard; 2021."},{"key":"10.1016\/j.vaccine.2022.05.087_b0045","unstructured":"World Health Organization W. Tracking SARS-CoV-2 variants; 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.087_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1995-7645.334716","article-title":"SARS-CoV-2 variants: a continuing threat to global health","volume":"15","author":"Shanmugaraj","year":"2022","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.vaccine.2022.05.087_b0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41392-021-00623-2","article-title":"SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern","volume":"6","author":"Noh","year":"2021","journal-title":"Signal Transd Target Therapy"},{"issue":"19","key":"10.1016\/j.vaccine.2022.05.087_b0060","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 variants \u2014 clinical, public health, and vaccine implications","volume":"384","author":"Abdool Karim","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.087_b0065","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.087_b0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.087_b0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.087_b0080","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.087_b0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.05.087_b0090","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.vaccine.2022.05.087_b0095","unstructured":"World Health Organization W. COVID-19 vaccine tracker and landscape; 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.087_b0100","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vacc"},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.087_b0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","article-title":"A comprehensive review of the global efforts on COVID-19 vaccine development","volume":"7","author":"Li","year":"2021","journal-title":"ACS Cent Sci"},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.087_b0110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.087_b0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.087_b0120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2022.05.087_b0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.087_b0130","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/vaccines9070744","article-title":"Immunogenicity studies of plant-produced SARS-CoV-2 receptor binding domain-based subunit vaccine candidate with different adjuvant formulations","volume":"9","author":"Siriwattananon","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.05.087_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2021.682953","article-title":"Plant-produced receptor-binding domain of SARS-CoV-2 elicits potent neutralizing responses in mice and non-human primates","volume":"12","author":"Siriwattananon","year":"2021","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.vaccine.2022.05.087_b0140","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Council","year":"2011"},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.087_b0145","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3201\/eid2712.211772","article-title":"Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine","volume":"27","author":"Hunsawong","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.087_b0150","unstructured":"CDC. 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes; 2020."},{"issue":"1-2","key":"10.1016\/j.vaccine.2022.05.087_b0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2022.05.087_b0160","doi-asserted-by":"crossref","unstructured":"Sheets RL, Stein J, Manetz TS, Andrews C, Bailer R, Rathmann J, et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006;91:620\u201330.","DOI":"10.1093\/toxsci\/kfj170"},{"key":"10.1016\/j.vaccine.2022.05.087_b0165","doi-asserted-by":"crossref","unstructured":"Planty C, Chevalier G, Duclos M-\u00c8, Chalmey C, Thirion-Delalande C, Sobry C, et al. Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine. 2020;40:748\u201362.","DOI":"10.1002\/jat.3941"},{"key":"10.1016\/j.vaccine.2022.05.087_b0170","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.tmaid.2020.101830","article-title":"SARS-CoV-2 jumping the species barrier: zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus","volume":"37","author":"Dhama","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.087_b0175","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/jmv.27532","article-title":"SARS-CoV-2 omicron variant: Could it be another threat?","volume":"94","author":"Shanmugaraj","year":"2022","journal-title":"J Med Virol"},{"issue":"6499","key":"10.1016\/j.vaccine.2022.05.087_b0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.087_b0185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.05.087_b0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.vaccine.2022.05.087_b0195","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.087_b0200","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41467-021-21634-1","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","volume":"12","author":"Liang","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.087_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008548","article-title":"Developing a low-cost and accessible COVID-19 vaccine for global health","volume":"14","author":"Hotez","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.05.087_b0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.087_b0215","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/pbi.13657","article-title":"Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases","volume":"19","author":"Lobato G\u00f3mez","year":"2021","journal-title":"Plant Biotechnol J"},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.087_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10081051","article-title":"Potential for developing plant-derived candidate vaccines and biologics against emerging coronavirus infections","volume":"10","author":"Shanmugaraj","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.05.087_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119750","article-title":"Investigational new drug enabling angiotensin oral-delivery studies to attenuate pulmonary hypertension","volume":"233","author":"Daniell","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.vaccine.2022.05.087_b0230","doi-asserted-by":"crossref","unstructured":"Daniell H, Rai V, Xiao Y. Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes. 2019;17:1357\u201368.","DOI":"10.1111\/pbi.13060"},{"key":"10.1016\/j.vaccine.2022.05.087_b0235","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/pbi.12604","article-title":"Plant-based oral vaccines against zoonotic and non-zoonotic diseases","volume":"14","author":"Shahid","year":"2016","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.vaccine.2022.05.087_b0240","series-title":"Biomedical innovations to combat COVID-19","first-page":"213","article-title":"Chapter 12 - SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines","author":"Shanmugaraj","year":"2022"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.087_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/plants9070842","article-title":"Plant molecular farming: a viable platform for recombinant biopharmaceutical production","volume":"9","author":"Shanmugaraj","year":"2020","journal-title":"Plants"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.087_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9020148","article-title":"Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development","volume":"9","author":"Shanmugaraj","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.05.087_b0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cbpa.2017.02.007","article-title":"Expression and functional evaluation of biopharmaceuticals made in plant chloroplasts","volume":"38","author":"Zhang","year":"2017","journal-title":"Curr Opin Chem Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.087_b0260","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/pbi.12462","article-title":"Low-cost oral delivery of protein drugs bioencapsulated in plant cells","volume":"13","author":"Kwon","year":"2015","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.vaccine.2022.05.087_b0265","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1467-7652.2008.00330.x","article-title":"Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure","volume":"6","author":"Strasser","year":"2008","journal-title":"Plant Biotechnol J"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.087_b0270","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/14712598.2015.1069271","article-title":"Using glyco-engineering to produce therapeutic proteins","volume":"15","author":"Dicker","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"24","key":"10.1016\/j.vaccine.2022.05.087_b0275","first-page":"2320","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle","volume":"383","author":"Keech","year":"2020","journal-title":"Vaccine"},{"issue":"10261","key":"10.1016\/j.vaccine.2022.05.087_b0280","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(20)32014-6","article-title":"Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18\u201364 years) and older adults (\u226565 years): two multicentre, randomised phase 3 trials","volume":"396","author":"Ward","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.087_b0285","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74904-1","article-title":"Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana","volume":"10","author":"Rattanapisit","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.05.087_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.589995","article-title":"Monoclonal antibodies B38 and H4 produced in nicotiana benthamiana neutralize SARS-CoV-2 in vitro","volume":"11","author":"Shanmugaraj","year":"2020","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.vaccine.2022.05.087_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.612781","article-title":"Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoor farms into biomanufacturing facilities","volume":"11","author":"Diego-Martin","year":"2020","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.vaccine.2022.05.087_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2021.589940","article-title":"SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients","volume":"12","author":"Makatsa","year":"2021","journal-title":"Front Plant Sci"},{"issue":"8","key":"10.1016\/j.vaccine.2022.05.087_b0305","doi-asserted-by":"crossref","first-page":"e0253574","DOI":"10.1371\/journal.pone.0253574","article-title":"Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies","volume":"16","author":"Rattanapisit","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.05.087_b0310","doi-asserted-by":"crossref","first-page":"604663","DOI":"10.3389\/fpls.2020.604663","article-title":"Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2","volume":"11","author":"Siriwattananon","year":"2021","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.vaccine.2022.05.087_b0315","doi-asserted-by":"crossref","first-page":"589833","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for Coronavirus Vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.05.087_b0320","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J Med Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.087_b0325","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.087_b0330","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.087_b0335","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J Virol"},{"issue":"7853","key":"10.1016\/j.vaccine.2022.05.087_b0340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.087_b0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21639-w","article-title":"Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques","volume":"12","author":"Yadav","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.05.087_b0350","first-page":"313","article-title":"The contribution of non-human primate models to the development of human vaccines","volume":"18","author":"Rivera-Hernandez","year":"2014","journal-title":"Discov Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.087_b0355","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.scr.2016.08.013","article-title":"Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease","volume":"17","author":"Grow","year":"2016","journal-title":"Stem Cell Res"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.087_b0360","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41423-021-00809-2","article-title":"Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates","volume":"19","author":"Pillet","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.087_b0365","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:49Z","timestamp":1759403749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":73,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22007356"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.087","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}